Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 429.93B |
| Revenue (ttm) | 78.81B |
| Net Income (ttm) | 21.48B |
| Shares Out | n/a |
| EPS (ttm) | 8.85 |
| PE Ratio | 20.01 |
| Forward PE | 18.45 |
| Dividend | 4.57 (2.60%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 1,048 |
| Average Volume | 485 |
| Open | 177.70 |
| Previous Close | 178.02 |
| Day's Range | 175.84 - 179.94 |
| 52-Week Range | 129.00 - 180.12 |
| Beta | n/a |
| RSI | 67.81 |
| Earnings Date | Jan 21, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
3 Superb Dividend Stocks to Hold for the Next 20 Years
Johnson & Johnson is a financial fortress with a solid pipeline and portfolio. Coca-Cola has an asset-light model that drives its profitability.
Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years
Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.
JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by...
1 Reason Why Shares of Johnson & Johnson Are Surging This Month
A spate of promising news is helping to extend a post-earnings rally for the healthcare giant's shares.
Johnson & Johnson (JNJ) Notable in Active Option Trading
Johnson & Johnson (JNJ) Notable in Active Option Trading
Ex-Dividend Reminder: Vertiv Holdings, Primo Brands and Johnson & Johnson
Looking at the universe of stocks we cover at Dividend Channel, on 11/25/25, Vertiv Holdings Co (Symbol: VRT), Primo Brands Corp (Symbol: PRMB), and Johnson & Johnson (Symbol: JNJ) will all trade ex-d...
Dividend Roundup: Nvidia, Home Depot, Nike, Johnson & Johnson, and more
Get the latest dividend increases and upcoming ex-dividend dates for top stocks.
Noteworthy Thursday Option Activity: JNJ, MRNA, ALB
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Johnson & Johnson (Symbol: JNJ), where a total volume of 39,084 contracts has been trad...
A Closer Look at Johnson & Johnson's Options Market Dynamics
Investors with a lot of money to spend have taken a bullish stance on Johnson & Johnson (NYSE: JNJ). And retail traders should know. We noticed this today when the trades showed up on publicly availa...
J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis
J&J (JNJ) stock and Halozyme Therapeutics (HALO) stock are in focus as their multiple myeloma therapy Darzalex Faspro is granted traditional FDA nod. Read more here.
Why Johnson & Johnson's Share Price Is Popping This Month
J&J beat Wall Street estimates on sales and profits in the third quarter. The company recently announced the acquisition of a biotech with an innovative cancer treatment.
Pre-Market Most Active for Nov 19, 2025 : TSLL, SQQQ, NVDA, NOK, SEMR, TQQQ, MSTX, IBIT, TGT, JNJ, BX, KMI
The NASDAQ 100 Pre-Market Indicator is up 101.25 to 24,604.35. The total Pre-Market volume is currently 321,403,216 shares traded.The following are the most active stocks for the pre-market session: D...
Why biotech and drug stocks are on the mend even though the rest of the market is hurting
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.
Johnson & Johnson (JNJ) Stock Performance and Strategic Moves
Johnson & Johnson (JNJ) Stock Performance and Strategic Moves
Johnson & Johnson falls after six-sessions of gain
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
Johnson & Johnson (JNJ) Drives Strategic Advancements in Zymeworks' Cash Flow Initiatives
Johnson & Johnson (JNJ) Drives Strategic Advancements in Zymeworks' Cash Flow Initiatives
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.
Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedent...
After Hours Most Active for Nov 17, 2025 : NVDA, CSCO, F, PFE, RUN, INTC, KDP, HBAN, HPE, JNJ, BAC, KO
The NASDAQ 100 After Hours Indicator is up 1.14 to 24,801.06. The total After hours volume is currently 130,344,085 shares traded.The following are the most active stocks for the after hours session: ...
Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition
Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition
Johnson & Johnson Adds Prostate Cancer Candidate In Around $3 Billion Halda Deal
Johnson & Johnson (NYSE: JNJ) on Monday agreed to acquire Halda Therapeutics OpCo, Inc . for $3.05 billion in cash . Halda is a clinical-stage biotechnology company with a proprietary Regulated Induc...
Johnson & Johnson's (JNJ) Tremfya Shows Promising Results in Psoriatic Arthritis Study
Johnson & Johnson's (JNJ) Tremfya Shows Promising Results in Psoriatic Arthritis Study